Maricann Group (CNSX:MARI – Get Free Report) received a $7.50 target price from stock analysts at National Bankshares in a research note issued on Thursday,BayStreet.CA reports. The brokerage currently has an “outperform” rating on the stock.
Separately, BMO Capital Markets increased their target price on shares of Maricann Group from $5.50 to $5.75 in a research report on Friday, November 29th.
View Our Latest Analysis on Maricann Group
Maricann Group Stock Performance
About Maricann Group
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Featured Articles
- Five stocks we like better than Maricann Group
- How to Profit From Growth Investing
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- About the Markup Calculator
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Canadian Penny Stocks: Can They Make You Rich?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
